|By PR Newswire||
|August 26, 2013 09:09 AM EDT||
NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.
There are today 881 companies plus partners developing 1527 biological drugs in 3359 developmental projects in cancer. In addition, there are 24 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 889 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 604 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 82 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
How May Drug Pipeline Update Be of Use?* Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.Drug Pipeline Update at a Glance
InvestigatorsIncludes more than 881 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & SynonymsLists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 1527 biological drugs in development, which have a total of 3359 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
Phase III# 109
Phase II# 371
Phase I# 405
No Data# 12
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Included biological drugs are also in development for 337 other indications, where of 115 are different cancer indications.
Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
TargetsMutationsAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
The identity of available biological structures on 349 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4087 structures available today among drug targets.
Identified drugs are linked to more than 604 different targets, divided into 82 classifications of molecular function:- Acid phosphatase activity- Antigen binding- ATPase activity- Auxiliary transport protein activity- B cell receptor activity- Binding- Carboxy-lyase activity- Carboxypeptidase activity- Catalytic activity- Cell adhesion molecule activity- Chaperone activity- Chemokine activity- Cofactor binding- Complement activity- Cysteine-type peptidase activity- Cytokine activity- Cytoskeletal protein binding- Deaminase activity- Defense/immunity protein activity- DNA binding- DNA repair protein- DNA topoisomerase activity- DNA-directed DNA polymerase activity- DNA-directed RNA polymerase activity- DNA-methyltransferase activity- Extracellular ligand-gated ion channel activity- Extracellular matrix structural constituent- Fucosyltransferase activity- G-protein coupled receptor activity- Growth factor activity- Growth factor binding- GTPase activator activity- GTPase activity- Guanylate cyclase activity- Heat shock protein activity- Hormone activity- Hydrolase activity- Intracellular ligand-gated ion channel activity- Isomerase activity- Kinase activity- Kinase binding- Kinase regulator activity- Ligand-dependent nuclear receptor activity- Ligase activity- Lipid kinase activity- Lipid phosphatase activity- Metallopeptidase activity- MHC class I receptor activity- Molecular function unknown- Motor activity- Oxidoreductase activity- Peptidase activity- Peptide hormone- Peroxidase activity- Protease inhibitor activity- Protein binding- Protein serine/threonine kinase activity- Protein threonine/tyrosine kinase activity- Protein tyrosine/serine/threonine phosphatase activity- Protein-tyrosine kinase activity- Receptor activity- Receptor binding- Receptor signaling complex scaffold activity- Receptor signaling protein serine/threonine kinase activity- Receptor signaling protein tyrosine phosphatase activity- RNA binding- RNA-directed DNA polymerase activity- Serine-type peptidase activity- Signal transducer activity- Structural constituent of cytoskeleton- Structural molecule activity- Superoxide dismutase activity- T cell receptor activity- Transcription factor activity- Transcription regulator activity- Transferase activity- Translation regulator activity- Transmembrane receptor activity- Transmembrane receptor protein tyrosine kinase activity- Transporter activity- Ubiquitin-specific protease activity- Unclassified
Identified targets are categorized into 38 different primary and alternate sub-cellular localizations:
- Apical membrane
- Cell junction
- Cell surface
- Clathrin-coated vesicle
- Cytoplasmic vesicle
- Early endosome
- Endoplasmic reticulum
- Extracellular matrix
- Golgi apparatus
- Golgi membrane
- Immunological synapse
- Integral to membrane
- Late endosome
- Membrane fraction
- Mitochondrial matrix
- Mitochondrial membrane
- Perinuclear region
- Perinuclear vesicle
- Peroxisomal matrix
- Plasma membrane
- Sarcoplasmic reticulum
- Secretory granule
- Secretory vesicle
- Soluble fraction
Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile
Direct links are provided from inside the application to 716 protein expression profiles of 470 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway ReferalsIdentified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.- BioCarta# 265 Pathways- KEGG# 194 Pathways- NCI-Nature# 251 Pathways- NetPath# 32 Pathways
Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
MechanismIn total there are different drug mechanism of action represented in this Drug Pipeline Update.
Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
CompoundIdentified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & SynonymsPresentation of drug name and synonyms
Principal Company & Partners
Presentation of principal company and partners
Target and Molecular Function of TargetDescribed target(s) is/are presented with:Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
MutationAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted PathwaysDescribed target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Drug mechanism of action
Developmental ProjectsSummary field of developmental projects for the drug, including indication, developmental stage and status.Example:Cancer, myeloma – Phase II Clinical Trial – ActiveCancer, prostate – Phase III Clinical Trial – Ceased
Short introduction to drug
Compound DataCompound type, Chemical name, CAS Number and molecular weight
Available patent information related to the drug is presented here.
Fillings and ApprovalsApprovals and submissionsAnalyst comments
Deals & Licensing
Collaborations and deals
Availability for licensing
Phase IV DataAvailable Phase IV development data, developmental history and scientific data.
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II DataAvailable Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Phase 0 DataAvailable Phase 0 development data, developmental history and scientific data.
Available preclinical development data, developmental history and scientific data.
Discovery DataAvailable discovery development data, developmental history and scientific data.
Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies
Dynamic Report GeneratorOur dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
System Requirements- Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)- Browser Application (Internet Explorer)- Internet access (to access related internet resources)
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
Docker is hot. However, as Docker container use spreads into more mature production pipelines, there can be issues about control of Docker images to ensure they are production-ready. Is a promotion-based model appropriate to control and track the flow of Docker images from development to production? In his session at DevOps Summit, Fred Simon, Co-founder and Chief Architect of JFrog, will demonstrate how to implement a promotion model for Docker images using a binary repository, and then show h...
Oct. 9, 2015 04:45 AM EDT
As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ability. Many are unable to effectively engage and inspire, creating forward momentum in the direction of desired change. Renowned for its approach to leadership and emphasis on their people, organizations increasingly look to our military for insight into these challenges.
Oct. 9, 2015 04:45 AM EDT
Achim Weiss is Chief Executive Officer and co-founder of ProfitBricks. In 1995, he broke off his studies to co-found the web hosting company "Schlund+Partner." The company "Schlund+Partner" later became the 1&1 web hosting product line. From 1995 to 2008, he was the technical director for several important projects: the largest web hosting platform in the world, the second largest DSL platform, a video on-demand delivery network, the largest eMail backend in Europe, and a universal billing syste...
Oct. 9, 2015 04:45 AM EDT
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively.
Oct. 9, 2015 04:15 AM EDT
DevOps and Continuous Delivery software provider XebiaLabs has announced it has been selected to join the Amazon Web Services (AWS) DevOps Competency partner program. The program is designed to highlight software vendors like XebiaLabs who have demonstrated technical expertise and proven customer success in DevOps and specialized solution areas like Continuous Delivery. DevOps Competency Partners provide solutions to, or have deep experience working with AWS users and other businesses to help t...
Oct. 9, 2015 04:00 AM EDT Reads: 214
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Oct. 9, 2015 04:00 AM EDT Reads: 281
The broad selection of hardware, the rapid evolution of operating systems and the time-to-market for mobile apps has been so rapid that new challenges for developers and engineers arise every day. Security, testing, hosting, and other metrics have to be considered through the process. In his session at Big Data Expo, Walter Maguire, Chief Field Technologist, HP Big Data Group, at Hewlett-Packard, will discuss the challenges faced by developers and a composite Big Data applications builder, foc...
Oct. 9, 2015 04:00 AM EDT Reads: 498
Nowadays, a large number of sensors and devices are connected to the network. Leading-edge IoT technologies integrate various types of sensor data to create a new value for several business decision scenarios. The transparent cloud is a model of a new IoT emergence service platform. Many service providers store and access various types of sensor data in order to create and find out new business values by integrating such data.
Oct. 9, 2015 04:00 AM EDT Reads: 564
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction....
Oct. 9, 2015 04:00 AM EDT Reads: 220
Containers are changing the security landscape for software development and deployment. As with any security solutions, security approaches that work for developers, operations personnel and security professionals is a requirement. In his session at @DevOpsSummit, Kevin Gilpin, CTO and Co-Founder of Conjur, will discuss various security considerations for container-based infrastructure and related DevOps workflows.
Oct. 9, 2015 04:00 AM EDT Reads: 232
The cloud has reached mainstream IT. Those 18.7 million data centers out there (server closets to corporate data centers to colocation deployments) are moving to the cloud. In his session at 17th Cloud Expo, Achim Weiss, CEO & co-founder of ProfitBricks, will share how two companies – one in the U.S. and one in Germany – are achieving their goals with cloud infrastructure. More than a case study, he will share the details of how they prioritized their cloud computing infrastructure deployments ...
Oct. 9, 2015 03:00 AM EDT Reads: 734
Chris Van Tuin, Chief Technologist for the Western US at Red Hat, has over 20 years of experience in IT and Software. Since joining Red Hat in 2005, he has been architecting solutions for strategic customers and partners with a focus on emerging technologies including IaaS, PaaS, and DevOps. He started his career at Intel in IT and Managed Hosting followed by leadership roles in services and sales engineering at Loudcloud and Linux startups.
Oct. 9, 2015 03:00 AM EDT Reads: 199
There are so many tools and techniques for data analytics that even for a data scientist the choices, possible systems, and even the types of data can be daunting. In his session at @ThingsExpo, Chris Harrold, Global CTO for Big Data Solutions for EMC Corporation, will show how to perform a simple, but meaningful analysis of social sentiment data using freely available tools that take only minutes to download and install. Participants will get the download information, scripts, and complete en...
Oct. 9, 2015 03:00 AM EDT Reads: 291
WebRTC services have already permeated corporate communications in the form of videoconferencing solutions. However, WebRTC has the potential of going beyond and catalyzing a new class of services providing more than calls with capabilities such as mass-scale real-time media broadcasting, enriched and augmented video, person-to-machine and machine-to-machine communications. In his session at @ThingsExpo, Luis Lopez, CEO of Kurento, will introduce the technologies required for implementing thes...
Oct. 9, 2015 03:00 AM EDT Reads: 721
Between the compelling mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at DevOps Summit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how busine...
Oct. 9, 2015 02:00 AM EDT Reads: 284